Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 5036 results found since Jan 2013.

Nanoparticles engineered with Rituximab and loaded with Nutlin-3 show promising therapeutic activity in B leukemic xenografts.
CONCLUSIONS: Our data demonstrate for the first time the potential anti-leukemic activity of Rituximab-engineered Nutlin-3 loaded NP in xenograft SCID mice. PMID: 23719263 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 29, 2013 Category: Cancer & Oncology Authors: Voltan R, Secchiero P, Ruozi B, Forni F, Agostinis C, Caruso L, Vandelli MA, Zauli G Tags: Clin Cancer Res Source Type: research

Preparation and Evaluation of APTES-PEG Coated Iron Oxide Nanoparticles conjugated to Rhenium-188 labeled Rituximab
Radioimmuno-conjugated (Rhenium-188 labeled Rituximab), 3 Aminopropyltriethoxy Silane (APTES)-polyethylene glycol (PEG) coated iron oxide nanoparticles were synthesized and then characterized. Therapeutic effect and targeting efficacy of complex were evaluated in CD20 express B cell lines and tumor bearing Balb/c mice respectively. To reach these purposes; Superparamagnetic Iron Oxide Nanoparticles (SPIONs) were synthesized using coprecipitation method and then their surface was treated with APTES for increasing retention time of SPIONs in blood circulation and amine group creation.
Source: Nuclear Medicine and Biology - May 6, 2016 Category: Nuclear Medicine Authors: Bakhtiar Azadbakht, Hossein Afarideh, Mohammad Ghannadi-Maragheh, Ali Bahrami-Samani, Mehdi Asgari Source Type: research

Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles.
Abstract Therapeutic monoclonal antibodies hold great promise in the treatment of cancer and other diseases, but their unclear mechanism of action makes it difficult to identify features that will increase their efficacy. One such feature may be antibody valence, since enhanced therapeutic efficacies have been observed using multivalent, as opposed to bivalent, antibodies. For example, multivalent antibody-lipid nanoparticles (Ab-LNPs) containing rituximab (Rtx) or trastuzumab show significantly increased therapeutic activity compared to equivalent doses of the bivalent antibodies. To more fully understand this ph...
Source: European Journal of Pharmaceutics and Biopharmaceutics - April 24, 2017 Category: Drugs & Pharmacology Authors: Popov J, Gilabert-Oriol R, Bally MB Tags: Eur J Pharm Biopharm Source Type: research

Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells.
Authors: Tang X, Xie C, Jiang Z, Li A, Cai S, Hou C, Wang J, Liang Y, Ma D Abstract The mTOR signal pathway is often highly activated in B-cell non-Hodgkin's lymphoma (NHL) and promotes cancer progression and chemo-resistance. Therefore, the pathways of mTOR are an important target for drug development in this disease. In the current study, we developed a rituximab (anti-CD20)-modified mTOR inhibitor, AZD-2014, loaded into nanoparticles (Ab-NPs-AZD-2014) for trial of its anti-NHL effect. In a cultured NHL cell line, Ab-NPs-AZD-2014 inhibited cancer cell growth, induced cell apoptosis, and blocked activation of mTOR...
Source: Artificial Cells, Nanomedicine and Biotechnology - September 12, 2018 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Cancers, Vol. 15, Pages 3618: Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia
Conclusions: AgNPs showed strong anti-leukemic activity in CLL, with the potential for clinical translation in combination with agents used in CLL. The increased specificity of AgNPs@Rituximab toward CLL cells could be relevant for overcoming in vivo AgNPs’ non-specific distribution and increasing their efficacy.
Source: Cancers - July 14, 2023 Category: Cancer & Oncology Authors: Francesco Maria Adamo Estevao Carlos Silva Barcelos Filomena De Falco Erica Dorillo Chiara Rompietti Daniele Sorcini Arianna Stella Beatrice Del Papa Stefano Baldoni Angela Esposito Clelia Geraci Roberta Arcaleni Chiara Pennetta Francesco Ragonese Lorenzo Tags: Article Source Type: research

Editor's Note: Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts
Clin Cancer Res. 2022 Jul 1;28(13):2971. doi: 10.1158/1078-0432.CCR-22-1597.NO ABSTRACTPMID:35775192 | DOI:10.1158/1078-0432.CCR-22-1597
Source: Clinical Cancer Research - July 1, 2022 Category: Cancer & Oncology Authors: Rebecca Voltan Paola Secchiero Barbara Ruozi Flavio Forni Chiara Agostinis Lorenzo Caruso Maria Angela Vandelli Giorgio Zauli Source Type: research

A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity)
Conclusions Though this is not a comprehensive summary of malignancies in PIDDs, or even lymphoproliferative disease in this area, this review summarizes the Medline-indexed published reports of B and T lymphomas in patients with PIDDs. This report highlights the diversity of malignant lymphoproliferative disorders in setting of PIDDs, and its associated challenges of diagnosis and treatment. The pathological classification and nomenclature for the lymphoid malignancies with variably reported and postulated underlying mechanisms were inconsistent and inadequate for many of these published reports. A wide range of treatmen...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome
CONCLUSIONS: This updated review strengthened the evidence that immunosuppressive therapy is probably superior to non-immunosuppressive therapy in inducing remission and reducing the number of patients that progress to ESKD. However, these benefits need to be balanced against the side effects of immunosuppressive drugs. The number of included studies with high-quality design was relatively small and most studies did not have adequate follow-up. Clinicians should inform their patients of the lack of high-quality evidence. An alkylating agent (cyclophosphamide or chlorambucil) combined with a corticosteroid regimen had short...
Source: Cochrane Database of Systematic Reviews - November 15, 2021 Category: General Medicine Authors: Thilo C von Groote Gabrielle Williams Eric H Au Yizhi Chen Anna T Mathew Elisabeth M Hodson David J Tunnicliffe Source Type: research

Interventions for focal segmental glomerulosclerosis in adults
CONCLUSIONS: No RCTs, which evaluated corticosteroids, were identified although the KDIGO guidelines recommend corticosteroids as the first treatment for adults with FSGS. The studies identified included participants with steroid-resistant FSGS. Treatment with cyclosporin for at least six months was more likely to achieve complete remission of proteinuria compared with other treatments but there was considerable imprecision due to few studies and small participant numbers. In future studies of existing or new interventions, the investigators must clearly define the populations included in the study to provide appropriate r...
Source: Cochrane Database of Systematic Reviews - February 28, 2022 Category: General Medicine Authors: Elisabeth M Hodson Aditi Sinha Tess E Cooper Source Type: research

Interventions for minimal change disease in adults with nephrotic syndrome
CONCLUSIONS: This updated review has identified evidence for the efficacy and adverse effects of CNIs and EC-MPS with or without reduced-dose prednisolone compared with prednisolone alone for the induction of remission in adults with MCD and nephrotic syndrome with some reductions in steroid-associated adverse events. RCT data on the efficacy and adverse effects of rituximab in adults with MCD are awaited. Further, adequately powered RCTs are required to determine the relative efficacies of CNIs and EC-MPS and to evaluate these medications in patients with relapsing or steroid-resistant disease.PMID:35230699 | DOI:10.1002/...
Source: Cochrane Database of Systematic Reviews - March 1, 2022 Category: General Medicine Authors: Karolis Azukaitis Suetonia C Palmer Giovanni Fm Strippoli Elisabeth M Hodson Source Type: research

Interventions for focal segmental glomerulosclerosis in adults
CONCLUSIONS: No RCTs, which evaluated corticosteroids, were identified although the KDIGO guidelines recommend corticosteroids as the first treatment for adults with FSGS. The studies identified included participants with steroid-resistant FSGS. Treatment with cyclosporin for at least six months was more likely to achieve complete remission of proteinuria compared with other treatments but there was considerable imprecision due to few studies and small participant numbers. In future studies of existing or new interventions, the investigators must clearly define the populations included in the study to provide appropriate r...
Source: Cochrane Database of Systematic Reviews - February 28, 2022 Category: General Medicine Authors: Elisabeth M Hodson Aditi Sinha Tess E Cooper Source Type: research

Biologic therapies and bone loss in rheumatoid arthritis
ConclusionTreatment with biologic drugs is associated with the decrease in bone loss. Studies with anti-TNF blocking agents show preservation or increase in spine and hip BMD and also a better profile of bone markers. Most of these studies were performed with infliximab. Only three epidemiological studies analyzed the effect on fractures after anti-TNF blocking agent ’s treatment. IL-6 blocking agents also showed improvement in localized bone loss not seen with anti-TNF agents. There are a few studies with rituximab and abatacept. Although several studies reported favorable actions of biologic therapies on bone protectio...
Source: Osteoporosis International - January 27, 2017 Category: Orthopaedics Source Type: research